Previous 10 | Next 10 |
Montrouge, France, February 22, 2022 DBV Technologies to Participate in Upcoming AAAAI 202 2 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced ...
Montrouge, France, February 14, 2022 DBV Technologies to Present at the 11th Annual SVB Leerink Global Healthcare Conferenc e DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, ...
Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market: NYSE Euronext Paris ISIN C...
Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ...
Montrouge, France, January 7, 2022 DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today...
Shares of DBV Technologies (DBVT +13.3%) have recouped some of their losses from yesterday after the company announced a new late-stage trial for its Viaskin peanut allergy patch. The trial will evaluate a modified patch that is 50% larger than a previous version. Kempen analyst Alex Cogut to...
BiondVax Pharmaceuticals (NASDAQ:BVXV) +55% signs definitive agreements for development and commercialization of innovative nanosized COVID-19 antibody therapy with Max Planck Institute of Biophysical Chemistry and University Medical Center Göttingen, Germany. BioRestorative Therapi...
Gainers: Reliance Global Group (NASDAQ:RELI) +89%. Biofrontera (NASDAQ:BFRI) +49%. IsoPlexis Corporation (NASDAQ:ISO) +37%. Chemomab Therapeutics (NASDAQ:CMMB) +29%. iSpecimen (NASDAQ:ISPC) +28%. Aldeyra Therapeutics (NASDAQ:ALDX) -51%. DBV Technologies...
Gainers: Reliance Global Group (NASDAQ:RELI) +82%. Biofrontera (NASDAQ:BFRI) +49%. Jaguar Health (NASDAQ:JAGX) +43%. IsoPlexis (NASDAQ:ISO) +31%. Aridis Pharmaceuticals (NASDAQ:ARDS) +28%. Petros Pharmaceuticals (NASDAQ:PTPI) +30%. Eqonex (NASDAQ:EQOS) +26%. Quantum-Si incorporated (NASDAQ:QS...
Shares of DBV Technologies (NASDAQ: DBVT) , a clinical-stage biopharmaceutical company, took a sharp turn for the worse today. Investors reacting to disappointing news about the development of Viaskin Peanut, its treatment for those with peanut allergies, pushed the stock 37.8% lowe...
News, Short Squeeze, Breakout and More Instantly...
DBV Technologies S.A. Company Name:
DBVT Stock Symbol:
NASDAQ Market:
DBV Technologies S.A. Website:
Châtillon, France, July 30, 2024 DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutic...
Châtillon, France, July 30, 2024 DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expecte...
Châtillon, France, July 29, 2024 DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, toda...